If you have paid any attention to health news in the last two years, you have encountered GLP-1s. Ozempic. Wegovy. Mounjaro. Zepbound. The drugs have been on magazine covers and in congressional hearings and on social media in a volume that makes them difficult to think about clearly. There is the breathless enthusiasm from people who have lost significant weight. There is the backlash about shortages and cost and the idea that people are taking the easy way out. There is the stock market moving on clinical trial results.
What is harder to find, in all of that noise, is a plain explanation of what these drugs actually are, what they actually do inside the body, and why they appear to work in a way that other approaches to weight management have not. That is what this article is.
No agenda. No sales pitch. Just the science, explained clearly enough to be useful.
Start With the Hormone
GLP-1 stands for glucagon-like peptide-1. It is not a drug. It is a hormone that your body produces naturally, specifically in cells in your small intestine called L-cells, in response to eating. When food reaches your gut, your L-cells release GLP-1 into the bloodstream, and that hormone sets off a cascade of responses that help your body manage the meal you just ate.
The hormone does several things at once. It signals the pancreas to release insulin, the hormone that moves glucose from the bloodstream into cells. It simultaneously suppresses glucagon, a hormone that would otherwise tell the liver to release more glucose into the blood. It slows gastric emptying, meaning food moves more slowly from the stomach into the small intestine, which flattens the spike in blood sugar after eating. And it signals the brain, particularly a region called the hypothalamus, that food has arrived and that appetite can be reduced.
In a person without metabolic dysfunction, this system works fairly well. You eat, GLP-1 rises, insulin is released in the right amount, blood sugar is managed, and the brain receives a signal that says something like: enough for now. The problem in people with type 2 diabetes, and to varying degrees in people with obesity, is that this system is impaired. The GLP-1 response is blunted. The brain’s satiety signals are less sensitive. The insulin response is inadequate. The result is a feedback loop where blood sugar stays high, hunger is not properly regulated, and weight management becomes genuinely harder than willpower alone can address.
GLP-1 is not a drug invented by a pharmaceutical company. It is a hormone your body already makes. The drugs are designed to mimic and extend its effects.
What the Drugs Do That the Hormone Does Not
The natural GLP-1 hormone has a half-life of roughly two minutes. Enzymes in the bloodstream, specifically a protein called DPP-4, break it down almost immediately after it is released. This is by design in normal physiology: the hormone does its job quickly and then clears. The problem is that you cannot take GLP-1 as a medication and expect it to do much, because it would be broken down before it had time to work.
What pharmaceutical researchers did, starting in the 1990s and accelerating through the 2000s and 2010s, was develop molecules that bind to the same receptors as GLP-1 but are structured differently enough that DPP-4 cannot break them down quickly. These GLP-1 receptor agonists, also called GLP-1 RAs, mimic the effects of the natural hormone but persist in the body for hours or days rather than minutes.
The first generation of these drugs, including exenatide and liraglutide, were significant but required daily injections and produced modest weight loss results in most patients. The current generation, semaglutide and tirzepatide, represented a step change in both convenience and efficacy.
Semaglutide: the molecule behind Ozempic and Wegovy
Semaglutide is a GLP-1 receptor agonist with a half-life of approximately one week, which is why it is administered as a weekly injection. It is the active ingredient in both Ozempic, which was approved for type 2 diabetes management, and Wegovy, which is the higher-dose version approved specifically for chronic weight management.
The drug works through the same mechanisms as natural GLP-1, but with sustained intensity. It keeps insulin secretion appropriately elevated in response to blood glucose. It keeps gastric emptying slowed. And it maintains the brain signaling that reduces appetite, not just for the two minutes after a meal but continuously. People on semaglutide consistently report that food simply becomes less interesting. Cravings quiet down. The internal monologue about eating that many people describe as a constant background presence gets softer. This effect, which researchers call reduced food noise, is the aspect of GLP-1 medications that people find most difficult to explain and most significant in practice.
Tirzepatide: the dual agonist behind Mounjaro and Zepbound
Tirzepatide, the active ingredient in Mounjaro and Zepbound, represents a further development. It is a dual agonist, meaning it activates not just GLP-1 receptors but also GIP receptors. GIP stands for glucose-dependent insulinotropic peptide, another incretin hormone that plays a complementary role in insulin secretion and metabolic regulation.
The combination appears to produce greater weight loss than GLP-1 alone in clinical trials. The SURMOUNT-1 trial, which was a large randomized controlled trial of tirzepatide for obesity, showed average weight loss of around twenty percent of body weight at the highest dose over seventy-two weeks. For context, previous generations of weight loss medications produced average losses of five to eight percent. The difference is not incremental.
Why This Is Different From Previous Weight Loss Drugs
To understand why GLP-1 medications represent a genuine shift rather than just another entry in a long line of weight loss products, it helps to understand what made previous approaches fall short.
Most weight loss interventions, whether dietary, behavioral, or pharmaceutical, run into the same problem: the body treats significant weight loss as a threat. When you lose weight through calorie restriction, your body responds by lowering its metabolic rate, increasing hunger hormones like ghrelin, decreasing satiety hormones like leptin, and generally making every subsequent meal feel more urgent and more satisfying than it did at a higher weight. This is not a character flaw. It is a deeply conserved biological response designed to protect against starvation, and it operates largely below the level of conscious decision-making.
Previous weight loss drugs tried to work around this system in ways that turned out to be either ineffective, unsustainable, or dangerous. Stimulant-based medications raised heart rate and blood pressure alongside suppressing appetite. Fen-phen, the combination drug pulled from the market in 1997, caused heart valve damage. Even relatively recent approved medications produced modest results that did not meaningfully outperform lifestyle intervention alone in most patients.
GLP-1 medications work differently because they are not forcing the body to do something against its own regulatory systems. They are amplifying signals the body already uses to manage hunger and metabolism. The satiety the brain receives on semaglutide is not artificial in the way that a stimulant-induced appetite suppression is. It is the same signal the brain has always used to know that it has eaten enough, just sustained and strengthened.
On the “easy way out” framingA recurring criticism of GLP-1 medications is that they allow people to avoid doing the hard work of diet and exercise. This framing misunderstands what the drugs are doing. Obesity has a significant genetic and hormonal component. People with impaired GLP-1 signaling are not failing to try hard enough. They are operating with a metabolic system that is working against them in ways that willpower cannot reliably override. Using a medication to correct that impairment is not different in principle from using medication to correct any other hormonal deficiency. The analogy to insulin for type 1 diabetes is imperfect but instructive.
What They Do Beyond Weight Loss
The weight loss effects of GLP-1 medications are what captured public attention, but the clinical picture is broader than weight alone and in some ways more significant.
The SELECT trial, published in 2023, showed that semaglutide reduced the risk of major adverse cardiovascular events, including heart attack and stroke, by twenty percent in people with existing cardiovascular disease and overweight or obesity who did not have diabetes. This was not just a consequence of weight loss. The cardiovascular benefit appeared to be at least partially independent, suggesting that GLP-1 receptor activation has direct effects on cardiovascular function beyond what weight reduction alone would predict.
Research is accumulating on other potential benefits. There is evidence of reduced inflammation, which may have implications for conditions from arthritis to fatty liver disease. Trials are underway examining GLP-1 effects on sleep apnea, kidney disease, heart failure, addiction, and Alzheimer’s disease. Some of this research is early and some findings will not hold up. But the breadth of the signal is unusual and has shifted the scientific conversation about what these drugs are doing in the body.
The side effect profile is real and worth knowing. Nausea, vomiting, diarrhea, and constipation are the most common, particularly in the early weeks as the dose is titrated up. For most people these effects diminish significantly as the body adjusts. A small subset of people find them intolerable and discontinue. The more serious concerns, pancreatitis, thyroid c-cell tumors in animal studies, and gastroparesis in rare cases, are genuine considerations that should be discussed with a physician, not alarming enough to be dismissed and not common enough to be the reason most people hesitate.
The Question of Long-Term Use
One of the most important things to understand about GLP-1 medications is that for most people they are not a course of treatment with a defined end point. They are, for now, a long-term or indefinite medication in the way that a blood pressure drug or a cholesterol medication is.
The STEP 4 trial demonstrated this clearly. Participants who lost significant weight on semaglutide and then discontinued the medication regained most of it within a year. This is not a failure of the drug. It is a confirmation of the underlying biology: the medication is correcting an ongoing hormonal impairment, and when you stop taking it, the impairment returns. This is the same reason people with hypothyroidism take thyroid medication indefinitely and people with hypertension take antihypertensives indefinitely.
This has practical implications for how to think about these drugs. They are not a tool for losing weight and then stopping. They are a long-term intervention whose cost, availability, and side effect profile need to make sense on a sustained basis. The person who starts semaglutide should be thinking about a years-long relationship with the medication, not a six-month project.
The weight comes back when people stop. That is not a flaw in the drug. It is information about what the drug is actually doing.
Where the Science Currently Stands
GLP-1 medications are not miracle drugs. They produce significant results in most people who take them at therapeutic doses, more significant than anything that came before in this category, but they are not universal. Roughly ten to fifteen percent of people are non-responders who see minimal weight loss regardless of dose. Side effects lead a meaningful minority to discontinue. The cost remains a barrier for many people without insurance coverage, though this is changing as more manufacturers enter the market and generics begin to emerge.
What the science does support, with a strength of evidence unusual for a relatively new class of drugs, is that GLP-1 receptor agonists represent a genuine pharmacological advance in the treatment of obesity and metabolic disease. The clinical trials are large, randomized, and well-designed. The cardiovascular benefit is real. The mechanism is understood at a molecular level. The results in practice, for the people who take them and respond to them, are consistent with what the trials showed.
The hype around these medications is real and sometimes excessive. The dismissal of them as a shortcut or a fad is also real and unsupported by the evidence. The truth, as it usually is, sits in between and is more interesting than either extreme.
This article is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs with real side effects and contraindications. Please consult a qualified physician before starting or stopping any medication.